Navigation Links
Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors

sor genes, thereby promoting tumor growth. MGCD0103 is an orally-administered, selective HDAC inhibitor, which targets specific class I HDAC isotypes. Preclinical data suggest that these HDAC isotypes are important in cancer biology and, consequently, such selective HDAC inhibitors may have increased efficacy and reduced toxicity compared to non-selective inhibitors.

Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) (Trial 005)

Data presented in a poster session by Guillermo Garcia-Manero, M.D., principal investigator, Associate Professor of Medicine and Chief, Section of Myelodysplastic Syndromes, Department of Leukemia, M.D. Anderson Cancer Centre, demonstrated that combination treatment with MGCD0103 and Vidaza(r) (azacitidine for injection) resulted in a 30 percent response rate for all patients, and a 37 percent response rate in the active dose ranges previously reported. Of the 37 patients in this trial, eleven patients (two MDS patients and nine AML patients) experienced objective clinical responses. In addition, the combination therapy showed good pharmacodynamic properties and acceptable safety in these patients.

"MGCD0103 and Vidaza are two epigenetic agents that have demonstrated single-agent activity in AML and MDS," said Dr. Garcia-Manero. "In this study we found that these agents can be given together, and that the resulting clinical activity is better than expected from each agent alone."

"We are very encouraged by the single-agent activity to date in our Hodgkin's lymphoma trial. These patients have progressive disease after receiving multiple prior therapies and there are currently no approved alternative treatments available to them," said Donald F. Corcoran, President and Chief Executive Officer of MethylGene. "In addition, the responses in our Vidaza-MGCD0103 combination trial are consistent with our earlier data. The data from these two ongoing trials have given us potential direction for registratio
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:7/24/2014)... -- Uroplasty, Inc. (NASDAQ: UPI ), a medical ... proprietary products to treat voiding dysfunctions, today reported ... ended June 30, 2014.  Global revenue for ... 19% to $4.1 million, as compared to $3.4 ... year.  Total revenue for the fiscal first quarter ...
(Date:7/24/2014)... July 24, 2014  Mettler-Toledo International Inc. (NYSE: ... 2014.  Provided below are the highlights: , ... quarter compared with the prior year. Reported sales increased ... , Net earnings per diluted share as reported (EPS) ... of 2013. Adjusted EPS was $2.57, an increase of ...
(Date:7/24/2014)... 24, 2014 Amgen (NASDAQ: AMGN ) ... results on Tuesday, July 29, 2014, after the close of ... a conference call with the investment community at 2 p.m. ... Robert A. Bradway , chairman and chief executive officer, and ... audio of the conference call will be simultaneously broadcast over ...
Breaking Medicine Technology:Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14Amgen Announces Webcast of 2014 Second Quarter Financial Results 2
... March 12 Genta,Incorporated (Nasdaq: GNTA ) today announced ... 31, 2007. The Company noted,significant recent milestones, including:, ... biomarker initiates in melanoma -- New oral product, ... 505(b)(2) strategy -- Tesetaxel, a leading ...
... Achieve Weight Loss with Education & ... ... Findings in the Journal of,the American Medical Association on the largest ... prevention.,The combination of both personal contact and web-based support are,identified as ...
Cached Medicine Technology:Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 2Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 3Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 4Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 5Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 6Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 7Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 8Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 9Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 10Study Finds Personal and Web-Based Support Equal Weight Loss Success 2Study Finds Personal and Web-Based Support Equal Weight Loss Success 3Study Finds Personal and Web-Based Support Equal Weight Loss Success 4
(Date:7/25/2014)... be treated more quickly after Manchester research , ... blood test on arrival, is effective in reducing ... study shows., The findings of a research group ... could potentially make a huge difference to a ... most common reason for emergency hospital admission. In ...
(Date:7/25/2014)... some patients is real and is only natural. However, ... in Cancer , the incidence and effects of ... computed tomography (CT) lung cancer screening exams are far ... , "Unsubstantiated claims of systemic and harmful patient ... continue to delay implementation of CT lung cancer screening ...
(Date:7/25/2014)... Ross A. Clevens, MD, FACS, and ... join the exclusive Obagi Clinical Advisory Board, comprised of ... plastic surgeons and dermatologists. , Dr. Clevens recently ... of thought leaders held its first meeting in three ... give Obagi the opportunity to meet with eight of ...
(Date:7/25/2014)... A report released by the Juvenile Diabetes ... 2013 (July 1, 2012- June 30, 2013). , Outside of ... is the largest single funder of type 1 diabetes research ... with most of the top research centers. There is ... 1 diabetes in the near future. , Since the 2008 ...
(Date:7/25/2014)... HealthDay Reporter , THURSDAY, July ... girls and boys are getting the human papillomavirus (HPV) vaccine, ... officials said Thursday. The U.S. Centers for Disease Control ... 12 get the three-dose vaccine so that protection is in ... Yet, despite a slight increase over the year before, only ...
Breaking Medicine News(10 mins):Health News:Heart attack patients could be treated more quickly after Manchester research 2Health News:ACR statement on cancer study regarding patient anxiety from CT lung cancer screening 2Health News:Renowned Melbourne Plastic Surgeon to Join Private Medical Advisory Board 2Health News:Report: JDRF 2013 Annual Research Spending Down by $50 million 2Health News:Too Few Teens Receive HPV Shot, CDC Says 2Health News:Too Few Teens Receive HPV Shot, CDC Says 3
... George Dahlman, senior vice president of public policy for ... the U.S. Senate Subcommittee on Defense Appropriations, calling for ... at the Department of Defense (DoD). , , ... blood cancers, including chronic lymphocytic leukemia (CLL), lymphoma and ...
... ... DIA Meeting in San Diego, Calif. , ... Boston, Mass. (PRWEB) June 18, 2009 -- CenterWatch , ... annual surveys aimed at better understanding physician referrals to clinical trials and study volunteer ...
... healthcare alliance Innovation Celebration , , ANAHEIM, Calif., June ... medical devices SpA, Italy, yesterday introduced a new innovation in ... fit in the palm of a hand, can record a ... the thumbs. , , The ecg@home(TM) debuted at ...
... June 18 Vendormate, the market leader in vendor ... the role of president, effective immediately. Andy Monin, ... and developing strategic opportunities. , ... success of Vendormate, steadily guiding our processes, systems, and ...
... effect on relationships and lead to significant changes in how ... and emotional level, according a study in the June issue ... from Northern Ireland have come up with four key recommendations ... nine males and seven females, aged between 33 and 78. ...
... - 2009 rankings include 10 specialties and Honor Roll - ... Group today released its second annual rankings by specialty of ... and featured in the August issue of ... July 21. , , The 2009 America,s Best ...
Cached Medicine News:Health News:The Leukemia & Lymphoma Society Calls for Blood Cancer Research Program at the Department of Defense 2Health News:CenterWatch to Introduce Key Findings from Surveys on Physician Referrals to Clinical Trials and Clinical Trial Volunteer Experiences at DIA Meeting 2Health News:HealthFrontier Introduces New Innovation in Web-Based Remote Health Monitoring Technology 2Health News:Bill Hayes Promoted to President of Vendormate 2Health News:Stroke survivors report loss of sexual desire, blurred gender roles, anger and fatigue 2Health News:Stroke survivors report loss of sexual desire, blurred gender roles, anger and fatigue 3Health News:Stroke survivors report loss of sexual desire, blurred gender roles, anger and fatigue 4Health News:U.S. News Media Group Releases Rankings of America's Best Children's Hospitals 2Health News:U.S. News Media Group Releases Rankings of America's Best Children's Hospitals 3
... for this age group?, ,Babies and young ... of an MDI. , ,Dry powder devices ... achieve efficiency. , ,Traditional nebulizers have high ... often used for this age group are inefficient ...
... Compact Compressor is for active patients who ... and everywhere. The compressor is small and ... optionsworldwide AC compatibility (100 to 240V), 12 ... the freedom to take aerosol treatments away ...
... Compact sporty design and ... XL the product of choice ... and performance. The CompAir XL ... cord storage compartment and a ...
... The 50 psi MaxiCompressor, ... designed to run 24 hours ... week. It features a tamper-proof ... against unintentional increases or decreases ...
Medicine Products: